LearnGlossaryMarketStocksSuperinvestorsSign in

SPRY

ARS Pharmaceuticals, Inc.

Healthcare · $519M market cap

Verdict

We can't put a fair value on SPRY right now. Its earnings are too small compared with its share price for an earnings-based value to mean anything.

Business quality

1 of 5 clear the 10% bar. What are the Big Five?

Earnings per share growth—?
Equity per share growth-41.3% a year✗
Sales growth—?
Free cash flow growth12.3% a year✓
Return on invested capital-30.8%✗

Follow SPRY

Track it on your watchlist and see the full analysis. Free.

Create a free account

Insider activity

Since Sep 1, 2026: no open-market purchases and 1 other filing (stock awards, tax withholding and similar). Why purchases matter

Other filings

Smith Margaret Ekins

Chief Commercial Officer · 2026-09-01

Award

$5.8M

About ARS Pharmaceuticals, Inc.

ARS Pharmaceuticals, Inc. specializes in creating ARS-1, an innovative intranasal epinephrine spray utilizing advanced absorption technology. This product serves as a crucial intervention for individuals and their households who are susceptible to life-threatening allergic reactions caused by food, pharmaceuticals, or insect stings. Among its offerings is Neffy, a low-dose version of its intranasal epinephrine nasal…

Biotechnology

Fair value and Payback Price are estimates from the company's reported financials, not investment advice. Prices as of the close of Oct 3, 2026. How the Payback Price works